Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Capecitabine and oxaliplatin in patients with advanced or metastatic pancreatic adenocarcinoma

Trial Profile

Capecitabine and oxaliplatin in patients with advanced or metastatic pancreatic adenocarcinoma

Completed
Phase of Trial: Phase II

Latest Information Update: 12 Apr 2017

At a glance

  • Drugs Capecitabine (Primary) ; Oxaliplatin (Primary)
  • Indications Pancreatic cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 26 Feb 2017 Status changed from active, no longer recruiting to completed.
    • 23 Feb 2017 Planned End Date changed from 1 Nov 2016 to 1 Nov 2017.
    • 30 Aug 2016 Planned End Date changed from 1 Jul 2016 to 1 Nov 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top